BlackRock Future Health ETF (BMED) Valuation
BMED valuation today
Holdings combined · company data as of Oct 26, 2026- P/E (TTM)
- 93.9 trailing earnings
- Forward P/E
- 17.6 analyst estimates
- Price / sales
- 4.47
- Price / book
- 5.91
- EV / EBITDA
- 12.6
- Earnings yield
- 1.07% inverse of P/E
- Dividend yield
- 0.76% of the holdings
- Return on equity
- 6.3% combined
- Net margin
- 4.8% combined
- Beta
- 0.76 weighted, vs S&P 500
BMED valuation vs other stock ETFs
| ETF | P/E | Fwd P/E | P/S | P/B | Div. yield | ROE | Net margin | Loss-makers |
|---|---|---|---|---|---|---|---|---|
| BMED | 93.9 | 17.6 | 4.47 | 5.91 | 0.76% | 6.3% | 4.8% | 25.1% |
| SPY | 25.9 | 19.9 | 3.67 | 5.47 | 1.08% | 21.1% | 14.2% | 1.9% |
| QQQ | 34.2 | 23.4 | 5.93 | 9.27 | 0.58% | 27.1% | 17.4% | 6.9% |
| DIA | 20.9 | 18.4 | 3.16 | 5.52 | 1.55% | 26.4% | 15.1% | 0.0% |
| VTI | 28.2 | 19.4 | 3.31 | 5.00 | 1.07% | 17.7% | 11.8% | 4.6% |
| IWM | n/m | 13.9 | 1.25 | 2.03 | 1.38% | −1.7% | −1.0% | 28.1% |
Same method for every fund. n/m = not meaningful (combined trailing earnings below zero or close to it). Loss-makers = weight of holdings with negative trailing earnings.
BMED valuation by sector
| Sector | Weight | P/E | Fwd P/E | P/S | P/B | Div. yield | ROE |
|---|---|---|---|---|---|---|---|
| Healthcare | 94.3% | 93.9 | 17.6 | 4.47 | 5.91 | 0.76% | 6.3% |
BMED earnings yield vs bond yields
Earnings yield = earnings ÷ price (1 ÷ P/E). The gap to bond yields is a rough gauge of the extra return stocks are priced to deliver.
How BMED weight splits by P/E
Share of the covered weight in companies with a trailing P/E in each range.
BMED largest holdings: valuation
| Symbol | Company | Weight | P/E | Fwd P/E | P/S | Div. yield | Share of earnings |
|---|---|---|---|---|---|---|---|
| GILD | Gilead Sciences, Inc. | 5.58% | — | 15.6 | 6.4 | 2.10% | −10.63% |
| MRNA | Moderna, Inc. | 5.08% | — | 23.0 | 39.1 | — | −20.87% |
| DHR | Danaher Corporation | 5.05% | 40.8 | 23.8 | 6.4 | 0.70% | 13.89% |
| ABBV | AbbVie Inc. | 4.83% | 80.6 | 16.4 | 7.8 | 2.42% | 6.73% |
| TMO | Thermo Fisher Scientific Inc. | 4.17% | 37.1 | 24.2 | 5.5 | 0.27% | 12.62% |
| IQV | IQVIA Holdings Inc. | 3.85% | 33.2 | 18.4 | 2.6 | — | 13.05% |
| BIIB | Biogen Inc. | 3.73% | 41.3 | 13.9 | 3.4 | — | 10.15% |
| MTD | Mettler-Toledo International Inc. | 3.68% | 36.6 | 28.5 | 7.9 | — | 11.30% |
| VRTX | Vertex Pharmaceuticals Incorporated | 3.33% | 28.9 | 24.1 | 10.1 | — | 12.94% |
| MRK | Merck & Co., Inc. | 3.18% | 115.8 | 15.3 | 5.4 | 2.33% | 3.08% |
| ROP | Roche Holding AG | 2.91% | — | — | — | — | — |
| EW | Edwards Lifesciences Corporation | 2.87% | 51.5 | 25.6 | 7.7 | — | 6.24% |
| A | Agilent Technologies, Inc. | 2.53% | 34.1 | 23.9 | 6.6 | 0.59% | 8.33% |
| AMGN | Amgen Inc. | 2.50% | 26.9 | 16.7 | 6.1 | 2.33% | 10.47% |
| WAT | Waters Corporation | 2.38% | 110.6 | 24.8 | 9.2 | — | 2.42% |
| HALO | Halozyme Therapeutics, Inc. | 2.33% | 35.6 | 11.5 | 8.3 | — | 7.34% |
| GMAB | Genmab A/S | 2.21% | 29.1 | 15.1 | 5.5 | — | 8.52% |
| DXCM | DexCom, Inc. | 2.14% | 34.1 | 28.2 | 6.5 | — | 7.05% |
| ILMN | Illumina, Inc. | 1.91% | 49.0 | 40.3 | 8.8 | — | 4.37% |
| CRL | Charles River Laboratories International, Inc. | 1.73% | — | 22.4 | 3.6 | — | −3.10% |
| ARGX | argenx SE | 1.65% | 31.2 | 25.9 | 9.7 | — | 5.93% |
| PFE | Pfizer Inc. | 1.54% | 38.9 | 9.7 | 2.6 | 5.81% | 4.44% |
| GALD | Galderma Group N | 1.51% | — | — | — | — | — |
| GH | Guardant Health, Inc. | 1.44% | — | — | 18.0 | — | −3.56% |
| ROIV | Roivant Sciences Ltd. | 1.37% | — | — | 3,215.5 | — | −2.43% |
Share of earnings = the holding's part of the fund's combined trailing profit. Green: earns more than its weight; orange: less. Symbol links go to each company's key metrics.
About BMED valuation
Adding up its 43 holdings with company data, BMED trades at 93.9 times trailing earnings and 17.6 times analysts' forward estimates, with a price-to-book ratio of 5.91 and a dividend yield of 0.76%. Its earnings yield of 1.07% is 4.26 percentage points below the 5.33% yield to maturity of the U.S. bond market (AGG).
The ten largest holdings are 42.5% of the fund and earn 52.3% of its combined profit. Companies that lost money over the past year are 25.1% of the covered weight.
How these figures are calculated. Each ratio treats the fund as one company: the earnings, sales and book value of every holding are added up in proportion to its weight and divided into the fund's price. In practice that is a weighted harmonic mean, so a single stock with a very high P/E cannot distort the result, and loss-making companies reduce the fund's earnings instead of being dropped. Covers 88.6% of the fund's weight (U.S.-listed stocks with company data); company figures as of October 26, 2026.
Related: BMED chart, BMED performance, BMED holdings, BMED dividends.
BMED valuation FAQ
What is the P/E ratio of BMED?
Based on its holdings, BMED has a trailing P/E of 93.9 and a forward P/E of 17.6 (earnings of all covered holdings combined in proportion to their weights, as of October 26, 2026).
What is the earnings yield of BMED?
The trailing earnings yield is 1.07% (1 ÷ P/E) and the forward earnings yield 5.67%. For comparison the U.S. bond market (AGG) yields 5.33% to maturity and T-bills about 3.91%.
Is BMED more expensive than the S&P 500?
BMED trades at 93.9 times trailing earnings versus 25.9 for the S&P 500 (SPY); on forward estimates the figures are 17.6 and 19.9.
What is the price-to-book ratio of BMED?
The holdings of BMED trade at 5.91 times book value, with a combined return on equity of 6.3%.